Detection of the JAK2 V617F variant in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) has changed the MPN molecular diagnostics routine over recent years [1,2]. This evidence concerns the gene JAK2 and essential thrombocythemia.